For research and educational purposes only. Not medical advice.
Fasoracetam Reference
Educational, not medical advice reference for Fasoracetam: Nootropic, Cognitive; regulatory status, evidence posture, source review, and schedul…
Reference summary
Phase 2/3 ADHD program in adolescents with mGluR network mutations did not yield FDA approval. Earlier vascular dementia trials in Japan also did not advance.
Regulatory and posture
- Categories
- Nootropic, Cognitive
- Aliases
- NS-105, LAM-105
- Evidence posture
- human - Not FDA-approved. Adolescent ADHD program discontinued. Community nootropic framing extrapolates beyond the discontinued indications.
- Regulatory status
- No FDA-approved fasoracetam drug label. Developed by Nippon Shinyaku then licensed to Aevi Medical for adolescent ADHD with mGluR mutations; the program was discontinued after Phase 2/3 data.
- Content review status
- research reference